Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Immuneering CorporationNASDAQ: IMRX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $180.48K rose 94.9% year over year, ahead of the +15.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at -4.3% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +94.9% holds above the trailing-twelve-month pace of +15.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 698.89K USD
- Year-over-year change
- +81.5%
- 4-year CAGR
- +44.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 698.89K | +81.5% |
| FY2024 | 2024-12-31 | 385.07K | +9.4% |
| FY2023 | 2023-12-31 | 352.08K | -55.8% |
| FY2022 | 2022-12-31 | 796.79K | +400.9% |
| FY2021 | 2021-12-31 | 159.07K | — |
Depreciation & Amortization vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's LTM Mar 2026 depreciation & amortization of $531.13K is the 8th largest of the 11 companies compared; the peer median is $3.65M.
- Its year-over-year change of +15.1% is the 5th highest of 11, against a peer median of -3.6%.
- Over three fiscal years its annual growth of -4.3% compares with a peer median of +19.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.81M | -13.0% | +11.0% | 3469.8% | |
| LTM Mar 2026 | $6.86M | +34.4% | -13.4% | 340.1% | |
| LTM Mar 2026 | $6.32M | -1.1% | +23.7% | — | |
| LTM Mar 2026 | $4.95M | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $4.42M | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $2.88M | -16.2% | +25.6% | 6.4% | |
| LTM Mar 2026 | $2.84M | -8.0% | -25.0% | 10.1% | |
| LTM Mar 2026 | $531.13K | +15.1% | -4.3% | — | |
| LTM Mar 2026 | $284K | -92.5% | +29.3% | 4.9% | |
| LTM Mar 2026 | $122K | -6.2% | -36.3% | 0.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $56K | +229.4% | — | — |
| Peer median (excluding IMRX) | $3.65M | -3.6% | +19.6% | 8.6% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Depreciation & Amortization | 159.07K | 796.79K | 352.08K | 385.07K | 698.89K |
| Deferred Income Tax | (307.49K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.8M | 0 | 5.73M | 6.5M | 0 |
| Change in Working Capital | 900.42K | 1.72M | (974.64K) | (925.38K) | 3.82M |
| Accounts Receivables | 279.71K | 233.62K | 12.42K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (130.4K) | 1.76M | (1.11M) | (112.14K) | (400.8K) |
| Other Working Capital | 751.1K | (276.56K) | 119.84K | (813.24K) | 4.22M |
| Other Non-Cash Items | 130.24K | 3.9M | (601.59K) | 75.98K | 6.16M |
| Operating Cash Flow | (30.85M) | (44.1M) | (48.97M) | (55M) | (45.34M) |
| Capital Expenditures | (60.79K) | (742.49K) | (342.75K) | (84.88K) | (142.23K) |
| Acquisitions (Net) | 70.35K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (75.63M) | (50.1M) | (44.66M) | (5.41M) | (88.6M) |
| Sales of Investments | 75.62M | 92.68M | 52.3M | 31.93M | 0 |
| Other Investing Activities | (75.62M) | 0 | 0 | 0 | 247 |
| Investing Cash Flow | (75.62M) | 41.83M | 7.3M | 26.43M | (88.74M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 120.32M | 19K | 28.2M | 4.24M | 226.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (842.76K) | 0 | 241.07K | 1.07M | (147) |
| Financing Cash Flow | 144.26M | 19K | 28.44M | 5.3M | 226.58M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.8M | (2.25M) | (13.23M) | (23.26M) | 92.5M |
| Free Cash Flow | (30.91M) | (44.84M) | (49.31M) | (55.08M) | (45.49M) |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.